Genetic variability of glutathione S-transferases influences treatment outcome of breast cancer

Tumor Biology

Volumn 36, Issue 8, 2015, Pages 5925-5929

  Zhou, Liang ^a   Huang, Anzhong ^a   Zhang, Dawei ^a   Yao, Junliang ^a   Zhang, Yong ^a   Li, Xuejiao ^b  

^a FUDAN UNIVERSITY   (China)

^b CHENGDU MEDICAL COLLEGE   (China)

Author keywords

Breast cancer; Glutathione S transferases; Overall survival; Polymorphism; Response to chemotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; GLUTATHIONE TRANSFERASE; GLUTATHIONE TRANSFERASE M1; GLUTATHIONE TRANSFERASE P1; GLUTATHIONE TRANSFERASE T1; GLUTATHIONE S-TRANSFERASE M1; GLUTATHIONE S-TRANSFERASE T1; GSTP1 PROTEIN, HUMAN;

ADULT; ARTICLE; BREAST CANCER; CANCER MORTALITY; DRUG RESPONSE; FEMALE; GENE; GENE DELETION; GENETIC VARIABILITY; GENOTYPE; GSTM1 GENE; GSTP1 GENE; GSTT1 GENE; HUMAN; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; AGED; BREAST NEOPLASMS; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; PATHOLOGY; RISK FACTOR; TREATMENT OUTCOME;

ADULT; AGED; BREAST NEOPLASMS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; GLUTATHIONE S-TRANSFERASE PI; GLUTATHIONE TRANSFERASE; HUMANS; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; TREATMENT OUTCOME;

EID: 84940440580     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-015-3266-9     Document Type: Article

References (20)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59(4):225–49.
2. Carol D, Jiemin M, Leah B, Ahmedin J. Breast cancer statistics, 2013. CA Cancer J Clin. 2014;64:52–62.
3. Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science. 1999;286(5439):487–91.
4. Scripture CD, Sparreboom A, Figg WD. Modulation of cytochrome P450 activity: implications for cancer therapy. Lancet Oncol. 2005;6(10):780–9.
5. André F, Ciccolini J, Spano JP, Penault-Llorca F, Mounier N, Freyer G, et al. Personalized medicine in oncology: where have we come from and where are we going? Pharmacogenomics. 2013;14(8):931–9.
6. Landi S. Mammalian class theta GST and differential susceptibility to carcinogens: a review. Mutat Res. 2000;463(3):247–83.
7. Ruzza P, Rosato A, Rossi CR, Floreani M, Quintieri L. Glutathione transferases as targets for cancer therapy. Anticancer Agents Med Chem. 2009;9(7):763–77.
8. Oliveira AL, Oliveira Rodrigues FF, Dos Santos RE, Rozenowicz RL, Barbosa de Melo M. GSTT1, GSTM1, and GSTP1 polymorphisms as a prognostic factor in women with breast cancer. Genet Mol Res. 2014;13(2):2521–30.
9. Tulsyan S, Chaturvedi P, Agarwal G, Lal P, Agrawal S, Mittal RD, et al. Pharmacogenetic influence of GST polymorphisms on anthracycline-based chemotherapy responses and toxicity in breast cancer patients: a multi-analytical approach. Mol Diagn Ther. 2013;17(6):371–9.
10. Bai YL, Zhou B, Jing XY, Zhang B, Huo XQ, Ma C, et al. Predictive role of GSTs on the prognosis of breast cancer patients with neoadjuvant chemotherapy. Asian Pac J Cancer Prev. 2012;13(10):5019–22.
11. Mishra A, Chandra R, Mehrotra PK, Bajpai P, Agrawal D. Glutathione S-transferase M1 and T1 polymorphism and response to neoadjuvant chemotherapy (CAF) in breast cancer patients. Surg Today. 2011;41(4):471–6.
12. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47.
13. Wheeler HE, Gamazon ER, Stark AL, O’Donnell PH, Gorsic LK, Huang RS, et al. Genome-wide meta-analysis identifies variants associated with platinating agent susceptibility across populations. Pharmacogenomics J. 2013;13:35–43.
14. Tew KD. Glutathione-associated enzymes in anticancer drug resistance. Cancer Res. 1994;54(16):4313–20.
15. Oguri T, Fujiwara Y, Katoh O, Daga H, Ishikawa N, Fujitaka K, et al. Glutathione S-transferase-pi gene expression and platinum drug exposure in human lung cancer. Cancer Lett. 2000;156:93–9.
16. Ge J, Tian AX, Wang QS, Kong PZ, Yu Y, Li XQ, et al. The GSTP1 105Val allele increases breast cancer risk and aggressiveness but enhances response to cyclophosphamide chemotherapy in North China. PLoS One. 2013;8(6):e67589.
17. Tulsyan S, Chaturvedi P, Agarwal G, Lal P, Agrawal S, Mittal RD, et al. Pharmacogenetic influence of GST polymorphisms on anthracycline-based chemotherapy responses and toxicity in breast cancer patients: a multi-analytical approach. Mol Diagn Ther. 2013;17(6):371–9.
18. Duggan C, Ballard-Barbash R, Baumgartner RN, Baumgartner KB, Bernstein L, McTiernan A. Associations between null mutations in GSTT1 and GSTM1, the GSTP1 Ile (105) Val polymorphism, and mortality in breast cancer survivors. Springerplus. 2013;2:450.
19. Bai YL, Zhou B, Jing XY, Zhang B, Huo XQ, Ma C, et al. Predictive role of GSTs on the prognosis of breast cancer patients with neoadjuvant chemotherapy. Asian Pac J Cancer Prev. 2012;13(10):5019–22.
20. Liu J, Luo J, Wang Y, Li L, Yang S. Predictive potential role of glutathione S-transferases polymorphisms on prognosis of breast cancer. Int J Clin Exp Pathol. 2014;7(12):8935–40.